Edward Nash
Stock Analyst at Canaccord Genuity
(4.40)
# 483
Out of 4,876 analysts
81
Total ratings
50.7%
Success rate
21.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $394 → $420 | $300.75 | +39.65% | 9 | May 2, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Buy | $64 | $20.28 | +215.58% | 1 | Apr 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $14.77 | +218.21% | 10 | Apr 10, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $130 → $142 | $73.22 | +93.94% | 7 | Apr 1, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $0.55 | +1,530.43% | 2 | Feb 26, 2025 | |
| VRNA Verona Pharma | Maintains: Buy | $44 → $72 | $93.82 | -23.26% | 9 | Feb 12, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.25 | +220.00% | 2 | Feb 10, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $56 → $73 | $56.19 | +29.92% | 6 | Jan 28, 2025 | |
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $43.38 | +105.16% | 1 | Nov 25, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $15 → $14 | $2.34 | +498.29% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.41 | +467.38% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $20 | $3.05 | +555.74% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $2.37 | +238.27% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $4.35 | +290.80% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.15 | -6.98% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.81 | +9,844.75% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $36.52 | +124.53% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $2.32 | +3,348.28% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $13.86 | +246.32% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.75 | +11,204.35% | 1 | Nov 8, 2017 |
Madrigal Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $394 → $420
Current: $300.75
Upside: +39.65%
Celldex Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $64
Current: $20.28
Upside: +215.58%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $14.77
Upside: +218.21%
Corcept Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $130 → $142
Current: $73.22
Upside: +93.94%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $0.55
Upside: +1,530.43%
Verona Pharma
Feb 12, 2025
Maintains: Buy
Price Target: $44 → $72
Current: $93.82
Upside: -23.26%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.25
Upside: +220.00%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56 → $73
Current: $56.19
Upside: +29.92%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $43.38
Upside: +105.16%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $2.34
Upside: +498.29%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.41
Upside: +467.38%
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $3.05
Upside: +555.74%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $2.37
Upside: +238.27%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $4.35
Upside: +290.80%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.15
Upside: -6.98%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.81
Upside: +9,844.75%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $36.52
Upside: +124.53%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $2.32
Upside: +3,348.28%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $13.86
Upside: +246.32%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.75
Upside: +11,204.35%